Jacc: Cardiooncology最新文献

{"title":"Lung Cancer and Cardiovascular Disease","authors":"Malak El-Rayes MD ,&nbsp;Inbar Nardi Agmon MD, MPH ,&nbsp;Christopher Yu MBBS, PhD ,&nbsp;Nichanan Osataphan MD, PhD ,&nbsp;Helena A. Yu MD ,&nbsp;Andrew Hope MD ,&nbsp;Adrian Sacher MD ,&nbsp;Anthony F. Yu MD, MS ,&nbsp;Husam Abdel-Qadir MD, PhD ,&nbsp;Paaladinesh Thavendiranathan MD, SM","doi":"10.1016/j.jaccao.2025.05.003","DOIUrl":"10.1016/j.jaccao.2025.05.003","url":null,"abstract":"<div><div>Among patients with cancer, those with lung cancer have the highest prevalence of pre-existing cardiovascular disease (CVD) and the highest risk of cardiovascular events postdiagnosis. This is driven by shared risk factors, particularly smoking and socioeconomic factors, and common biology. Furthermore, multimodality therapies for lung cancer, including surgery, radiation, chemotherapy, immunotherapy, and targeted therapy, are associated with CVD. Improvements in prevention, screening, and therapy for lung cancer have led to improved cancer survival, increasing the relevance of CVD for overall survival and quality of life. This review provides an overview of lung cancer and its treatment and discusses drivers of CVD, risk assessment, surveillance, prevention, and treatment strategies.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 4","pages":"Pages 325-344"},"PeriodicalIF":12.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding Perspectives on Physical Activity and Cardiovascular Risk in Cancer Survivors","authors":"Fan Zhang MD,&nbsp;Wenlong Yu MD,&nbsp;Mengchen Yin PhD","doi":"10.1016/j.jaccao.2025.01.013","DOIUrl":"10.1016/j.jaccao.2025.01.013","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Page 320"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143833174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality-of-Care Measures for Cardio-Oncology","authors":"Vijay U. Rao MD, PhD ,&nbsp;Anita Deswal MD, MPH ,&nbsp;Daniel Lenihan MD ,&nbsp;Susan Dent MD ,&nbsp;Teresa Lopez-Fernandez MD ,&nbsp;Alexander R. Lyon MD ,&nbsp;Ana Barac MD, PhD ,&nbsp;Nicolas Palaskas MD ,&nbsp;Ming Hui Chen MD, MMSc ,&nbsp;Hector R. Villarraga MD ,&nbsp;Diego Sadler MD ,&nbsp;Courtney M. Campbell MD, PhD ,&nbsp;Kerry Skurka RN, BSN ,&nbsp;Matt J. Wagner ,&nbsp;Matthias Totzeck MD, PhD ,&nbsp;Kathryn J. Ruddy MD, MPH ,&nbsp;Paul Heidenreich MD ,&nbsp;Randal Thomas MD ,&nbsp;Daniel Addison MD ,&nbsp;Sarju Ganatra MD ,&nbsp;Joerg Herrmann MD","doi":"10.1016/j.jaccao.2024.11.003","DOIUrl":"10.1016/j.jaccao.2024.11.003","url":null,"abstract":"<div><div>This document serves as a perspective on quality assessments in the discipline of cardio-oncology. We aim to define the current landscape, identify needs for quality and outcome improvements, and propose a roadmap for establishing viable metrics to improve patient care. Specifically, this document: 1) addresses the current lack of measurable high-quality metrics in cardio-oncology and their implications; 2) highlights needs and topic-specific barriers; 3) illustrates the process and application of a measurable quality metric; and 4) provides a framework to demonstrate measurable value for the growing population of patients with cancer and cardiovascular diseases.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Pages 191-202"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intermuscular Fat and Physical Activity Levels Relative to Exercise Capacity Change During Breast Cancer Treatment","authors":"Lauren Daniel BS ,&nbsp;Moriah P. Bellissimo PhD ,&nbsp;Ralph B. D’Agostino Jr. PhD ,&nbsp;Kristine C. Olson PhD ,&nbsp;Amy C. Ladd PhD ,&nbsp;Kerryn W. Reding PhD ,&nbsp;Kathryn E. Weaver PhD ,&nbsp;Glenn J. Lesser MD ,&nbsp;Bonnie Ky MD, MSCE ,&nbsp;W. Gregory Hundley MD ,&nbsp;UPBEAT Study Team","doi":"10.1016/j.jaccao.2025.01.009","DOIUrl":"10.1016/j.jaccao.2025.01.009","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Pages 297-299"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing CAC Risk Post-RRSO","authors":"Binglin Li MD,&nbsp;Yan Wang MD,&nbsp;Ruijuan Chen MD","doi":"10.1016/j.jaccao.2024.12.008","DOIUrl":"10.1016/j.jaccao.2024.12.008","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Page 312"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balancing Promise and Evidence","authors":"Paschalis Karakasis MD, PhD(c) ,&nbsp;Dimitrios Patoulias MD, PhD ,&nbsp;Nikolaos Fragakis MD, PhD","doi":"10.1016/j.jaccao.2025.01.017","DOIUrl":"10.1016/j.jaccao.2025.01.017","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Pages 314-315"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes and Predictors of Severity of Immunotherapy-Related Myocarditis","authors":"Dame Idossa MD ,&nbsp;Joerg Herrmann MD ,&nbsp;Kathryn J. Ruddy MD, MPH","doi":"10.1016/j.jaccao.2025.03.001","DOIUrl":"10.1016/j.jaccao.2025.03.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Pages 249-251"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis","authors":"Carlo Fumagalli MD ,&nbsp;Adam Ioannou MBBS, BSc ,&nbsp;Francesco Cappelli MD ,&nbsp;Mathew S. Maurer MD ,&nbsp;Yousuf Razvi MBChB ,&nbsp;Aldostefano Porcari MD ,&nbsp;Mattia Zampieri MD ,&nbsp;Federico Perfetto MD, PhD ,&nbsp;Muhammad U. Rauf MBBS ,&nbsp;Ana Martinez-Naharro MD, PhD ,&nbsp;Lucia Venneri MD, PhD ,&nbsp;Aviva Petrie MSc ,&nbsp;Carol Whelan MD ,&nbsp;Ashutosh Wechalekar MD ,&nbsp;Helen Lachmann MD ,&nbsp;Philip N. Hawkins MD, PhD ,&nbsp;Iacopo Olivotto MD ,&nbsp;Raffaele Marfella MD, PhD ,&nbsp;Andrea Ungar MD, PhD ,&nbsp;Niccolò Marchionni MD ,&nbsp;Marianna Fontana MD, PhD","doi":"10.1016/j.jaccao.2025.01.018","DOIUrl":"10.1016/j.jaccao.2025.01.018","url":null,"abstract":"<div><h3>Background</h3><div>The prevalence and clinical impact of frailty in transthyretin cardiac amyloidosis (ATTR-CA) remains poorly characterized.</div></div><div><h3>Objectives</h3><div>This study aimed to evaluate the prevalence, clinical determinants, and prognostic significance of frailty in a large cohort of patients with ATTR-CA.</div></div><div><h3>Methods</h3><div>Frailty was assessed in 880 patients with ATTR-CA (median age 80 years [Q1-Q3: 75-84 years], 719 [81.7%] male) using the Clinical Frailty Scale (CFS). Frailty was analyzed as a continuous variable and categorized as CFS 1 to 3, CFS 4 or 5, CFS 6 or 7, and CFS 8 or 9.</div></div><div><h3>Results</h3><div>Frailty was observed in 502 (57.1%) patients (CFS 4 or 5: 364 [41.4%]; CFS 6 or 7: 129 [14.7%]; CFS 8 or 9: 9 [1.0%]). Independent predictors of worsening frailty included older age, female sex, non-p.(V142I) hereditary ATTR-CA variants, and National Amyloidosis Centre stage 3 disease. Mortality rates increased incrementally with frailty severity (deaths per 100 person-years: 2.9 vs 11.0 vs 21.1 vs 40.9; log-rank <em>P</em> &lt; 0.001). Frailty was independently associated with higher mortality risk across all age groups, genotypes, and disease stages.</div></div><div><h3>Conclusions</h3><div>Frailty is common in ATTR-CA and is independently linked to increased mortality risk. Incorporating frailty assessment alongside traditional markers enhances prognostication across genotypes and disease severities, particularly for short-term risk estimation.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Pages 268-278"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Long-Term Outcomes in ATTR-CM","authors":"Nowell M. Fine MD, SM","doi":"10.1016/j.jaccao.2025.01.007","DOIUrl":"10.1016/j.jaccao.2025.01.007","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Pages 294-296"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy","authors":"Ahmad Masri MD, MS ,&nbsp;Priyanka Bhattacharya MD ,&nbsp;Brent Medoff MD ,&nbsp;Ain U. Ejaz MD ,&nbsp;Miriam R. Elman MS, MPH ,&nbsp;Pranav Chandrashekar MD ,&nbsp;Lauren Ives MPH ,&nbsp;Alfonsina Mirabal Santos MD ,&nbsp;Sergio L. Teruya MD ,&nbsp;Yuanzi Zhao MD, PhD ,&nbsp;Shuaiqi Huang PhD ,&nbsp;Xiaofeng Wang PhD ,&nbsp;Brett W. Sperry MD ,&nbsp;Mathew S. Maurer MD ,&nbsp;Prem Soman MD, PhD ,&nbsp;Mazen Hanna MD","doi":"10.1016/j.jaccao.2024.12.005","DOIUrl":"10.1016/j.jaccao.2024.12.005","url":null,"abstract":"<div><h3>Background</h3><div>Tafamidis improved survival and decreased cardiovascular hospitalizations in the ATTR-ACT trial. Due to improved recognition and earlier diagnosis, the epidemiology of transthyretin amyloid cardiomyopathy (ATTR-CM) is rapidly evolving.</div></div><div><h3>Objectives</h3><div>The authors sought to evaluate the contemporary long-term outcomes of patients with ATTR-CM treated with tafamidis.</div></div><div><h3>Methods</h3><div>Patients with ATTR-CM who received at least 1 dose of tafamidis between 2018 and 2021 at 5 amyloidosis centers in the United States were enrolled. Primary outcome was all-cause mortality.</div></div><div><h3>Results</h3><div>Among 624 patients, mean age was 76.9 ± 8.4 years, 12.5% were female, 17.5% were Black, and 17.5% had variant ATTR-CM. At the time of tafamidis start, 52% had NYHA functional class II, 34% had NYHA functional class III, 40% were in National Amyloidosis Center (NAC) Stage ≥II, 38% were in Columbia Stage ≥II, and the median NT-proBNP level was 1,914 (Q1-Q3: 957-3914) pg/mL. Over a median follow-up of 43.2 months (Q1-Q3: 25.2-52.8 months), 241 patients (38.6%) died. The probability of freedom from death at 65 months was 54.1% (95% CI: 47.4%-60.4%). Similarly, restricting the cohort to patients who received tafamidis within 6 months of their ATTR-CM diagnosis (n = 397, 63.6%) showed similar results, with a survival probability of 49.6% (95% CI: 37.6%-60.5%) at 65 months.</div></div><div><h3>Conclusions</h3><div>In a contemporary cohort of tafamidis-treated patients with ATTR-CM, 39% of patients died over a median of 43 months. Further work is needed to improve our understanding of ATTR-CM, its natural history, and how to further improve survival and prevent progression of heart failure.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Pages 282-293"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}